Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis
Phase of Trial: Phase IV
Latest Information Update: 24 Jun 2019
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Bayer
- 19 Jun 2019 Status changed from active, no longer recruiting to completed.
- 20 May 2019 Planned End Date changed from 30 Apr 2019 to 31 May 2019.
- 12 Apr 2019 Planned End Date changed from 29 Mar 2019 to 30 Apr 2019.